Lucintel Forecasts The Global Beta-lactam And Beta-lactamase Inhibitor Market To Reach $62 Billion By 2030

By Author: Lucintel LLC
Total Articles: 4752
Comment this article

According to a market report by Lucintel, the future of the global beta-lactam and beta-lactamase inhibitor market looks promising with opportunities in the urinary tract infection (excluding cUTI), respiratory infection, skin infection, complicated urinary tract infection (cUTI), complicated intra-abdominal infections (cIAI), nosocomial pneumonia, and blood stream infection markets. The global beta-lactam and beta-lactamase inhibitor market is expected to reach an estimated $62 billion by 2030 from $35 billion in 2024 at a CAGR of 10.1% from 2024 to 2030. The major drivers for this market are significant R&D investments being made by numerous biotech companies and the increase in the prevalence of infectious diseases.
A more than 150-page report to understand trends, opportunity and forecast in global beta-lactam and beta-lactamase inhibitor market to 2030 by drug class (penicillin, cephalosporin, carbapenem, monobactam, and combination), disease (urinary tract infection (excluding cUTI), respiratory infection, skin infection, complicated urinary tract infection (cUTI), complicated intra-abdominal infections (cIAI), ...
... nosocomial pneumonia, blood stream infection, and others), route of administration (oral, intravenous, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World).
Lucintel forecasts that, within the drug class category, cephalosporin is expected to witness the highest growth over the forecast period as it helps prevent the growth of bacteria.
Within the application category, complicated urinary tract infection (cUTI) is expected to witness the highest growth due to the growing burden of sepsis, accompanied by a rapid increase in mortality rates.
Download sample by clicking on beta-lactam and beta-lactamase inhibitor market.
In terms of regions, APAC will remain the largest region over the forecast period due to rising consumption of beta-lactam and beta-lactamase inhibitors.
Novartis International, Allergan, Pfizer, Merck & Co, Abbott Laboratories, Mylan, F. Hoffmann-La Roche are the major suppliers in the beta-lactam and beta-lactamase inhibitor market.
This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost visit Lucintel's Analytics Dashboard.
About Lucintel
At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056
Explore Our Latest Publications
Infusion Chair Market
Injectable Cement Market
Injectable Potassium Phosphate Market
Kitchen Mixer Tap Market
Lawn and Garden Consumable Market